Advertisement
Canadian Journal of Cardiology

Reply to Du et al.—Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and Stroke

Published:September 21, 2022DOI:https://doi.org/10.1016/j.cjca.2022.09.017
      Thank you, Dr Du, for the commentary

      Du L, Wang P, Chen H, Zhang Y, Ma J. Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke. Can J Cardiol xxxxx.

      regarding our article, “The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis.”
      • Ali M.U.
      • Mancini G.
      • Fitzpatrick-Lewis D.
      • et al.
      The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis.
      The differential effectiveness of the 2 classes regarding the aforementioned critical end points was highlighted in the review’s results and discussion sections. In addition, distinctions were made on a clinical basis in the guideline (published in parallel) and specifically concerning the absence of dedicated trials for GLP-1RAs in patients with heart failure or chronic kidney disease. We do emphasise, with prominence, the issue of stroke reduction with GLP-1RAs as well.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Du L, Wang P, Chen H, Zhang Y, Ma J. Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke. Can J Cardiol xxxxx.

        • Ali M.U.
        • Mancini G.
        • Fitzpatrick-Lewis D.
        • et al.
        The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis.
        Can J Cardiol. 2022; 38: 1201-1210

      Linked Article